EarKart Limited has fulfilled its quarterly regulatory compliance obligations by submitting the mandatory certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31 March 2026. The submission demonstrates the company's adherence to regulatory requirements governing share dematerialization processes.

Regulatory Compliance Details

The certificate was submitted in compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. Company Secretary and Compliance Officer Preeti Srivastava filed the documentation with BSE Limited on 14 April 2026.

Share Transfer Agent Confirmation

Skyline Financial Services Private Limited, serving as the company's Registrar to an issue and Share Transfer Agent, issued the confirmation certificate dated 03 April 2026. The RTA confirmed that no physical share certificates were received for dematerialization of equity shares during the quarter ended 31 March 2026.

The certificate was signed by Parveen Sharma, Authorised Signatory of Skyline Financial Services Private Limited, and addressed to EarKart Limited's registered office in Sector-63, Noida, Uttar Pradesh.

Company Information

EarKart Limited operates under CIN U74999DL2021PLC399313 and maintains its registered office at A-133, Ground Floor, Sector-63, Gautam Buddha Nagar, Noida, Uttar Pradesh. The company's shares are listed on BSE Limited under the scrip code 544549 with ISIN INE1A8F01035.

The quarterly compliance certificate submission ensures transparency in the company's share dematerialization processes and maintains regulatory compliance with SEBI's depositories framework. This routine filing provides stakeholders with confirmation of proper share transfer procedures during the reporting quarter.

Earkart Limited has completed the dispatch of its postal ballot notice seeking shareholder approval for significant changes in the utilization of its Initial Public Offering (IPO) proceeds. The company has published newspaper advertisements in Financial Express (English) and Jansatta (Vernacular) on April 02, 2026, confirming the completion of notice dispatch to eligible shareholders.

Proposed Fund Reallocation Structure

The company originally raised net proceeds of ₹3906.79 lakhs through its IPO and now seeks to modify the deployment strategy. The proposed reallocation involves shifting ₹1304.69 lakhs from the Shop-in-Shop (SIS) business model expansion to new business verticals.

New Business Initiatives

Pharmaceutical Division: The company plans to allocate ₹250.00 lakhs towards pharmaceutical initiatives, including strategic acquisitions of hospitals, clinics, and pharmaceutical businesses. This expansion aligns with the company's objective of strengthening its presence in the healthcare and pharmaceutical sector.

Strategic Acquisitions: An allocation of ₹600.00 lakhs has been proposed for acquiring land, properties, and complementary businesses. The company intends to explore acquisitions in healthcare services, pharmaceutical distribution, medical products, and related areas to enhance operational capabilities and geographic presence.

Enhanced Working Capital: The working capital allocation increases from ₹2110.13 lakhs to ₹2610.13 lakhs, with the additional ₹854.69 lakhs supporting the company's existing business operations and SIS model expansion.

E-Voting Process and Timeline

The postal ballot is being conducted exclusively through remote e-voting, with no physical ballot forms being dispatched. The company has engaged National Securities Depository Limited (NSDL) to provide e-voting facilities, with M/s. Nikita Kothari & Associate appointed as the scrutinizer.

Regulatory Compliance and Communication

Pursuant to Regulation 30 and 47(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has notified BSE Limited about the completion of postal ballot notice dispatch. The notice has been made available on the company's website at www.earkart.in .

Shareholders whose email addresses are registered with the company or depositories have received the postal ballot notice electronically. The proposed variation requires approval from more than 90% of shareholders voting through the remote e-voting process.

Board Approval and Risk Assessment

The Board of Directors unanimously approved the proposed variation at its meeting held on March 30, 2026, with no directors voting against the resolution. The company has identified several risk factors associated with the new initiatives, including regulatory compliance challenges in the pharmaceutical sector, market competition, acquisition-related risks, and integration complexities.

The company expects the proposed changes to enhance profitability, improve cash flows, and strengthen its overall market position in the healthcare ecosystem.